DR. DANIEL JOHN BARUFFI O.D.
Prescription History 1982916458
Optometrist in Wilmington, DE
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. DANIEL JOHN BARUFFI O.D., an active Optometrist specialist practicing in Wilmington, DE. Our medical registry currently tracks 8 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 449 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 252 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2024)Rx (2024) | Avg Cost per FillCost / Fill | Vs. Other DE PrescribersVs. DE Avg |
|---|---|---|---|
| Latanoprost | 252 | $15.44 | ▲ More than typical |
About Latanoprost: Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). Show more ▾ It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness. A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA. In 2024, this provider wrote 252 Medicare prescriptions for Latanoprost, about 1.9 times the volume of the typical Delaware prescriber of this medication (134.5). Medicare paid an average of $15.44 per fill, versus $15.23 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average DE prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 581.4 30-Day Fills standardized to 30-day supplies 17,244 Days of Medication total across all patients in 2024 | |||
| Timolol Maleate | 75 | $40.07 | ≈ Typical |
About Timolol Maleate: This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Show more ▾ Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers. A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor. In 2024, this provider wrote 75 Medicare prescriptions for Timolol Maleate, about the same volume as the typical Delaware prescriber of this medication (69). Medicare paid an average of $40.07 per fill, versus $19.47 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average DE prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 200.1 30-Day Fills standardized to 30-day supplies 5,966 Days of Medication total across all patients in 2024 | |||
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 35 | $14.67▼ below DE avg | ▼ Less than typical |
About Dorzolamide-Timolol: This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Show more ▾ Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers, and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors. In 2024, this provider wrote 35 Medicare prescriptions for Dorzolamide-Timolol, about half the volume of the typical Delaware prescriber of this medication (80.2). Medicare paid an average of $14.67 per fill, versus $18.06 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average DE prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the DE average for this medication. 87.8 30-Day Fills standardized to 30-day supplies 2,634 Days of Medication total across all patients in 2024 | |||
| Brimonidine Tartrate | 24 | $62.82 | ▼ Less than typical |
About Brimonidine Tartrate: This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Show more ▾ Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details. A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION. In 2024, this provider wrote 24 Medicare prescriptions for Brimonidine Tartrate, about a third of the volume of the typical Delaware prescriber of this medication (58.5). Medicare paid an average of $62.82 per fill, versus $58.61 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average DE prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 43.6 30-Day Fills standardized to 30-day supplies 1,281 Days of Medication total across all patients in 2024 | |||
| LumiganBimatoprost | 18 | $627.50 | ▼ Less than typical |
About Lumigan: Bimatoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Show more ▾ Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure. A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION. In 2024, this provider wrote 18 Medicare prescriptions for Lumigan, about half the volume of the typical Delaware prescriber of this medication (40.5). Medicare paid an average of $627.50 per fill, versus $577.87 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average DE prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 47.5 30-Day Fills standardized to 30-day supplies 1,413 Days of Medication total across all patients in 2024 | |||
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 16 | $15.26 | ▼ Less than typical |
About Neomycin-Polymyxin-Dexameth: This medication is used to treat conditions involving swelling (inflammation) of the eyes and to treat or prevent bacterial eye infections. Show more ▾ This product contains neomycin and polymyxin, antibiotics that work by stopping the growth of bacteria. It also contains dexamethasone, an anti-inflammatory corticosteroid that works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections and may worsen them (such as infections caused by viruses, fungi, mycobacteria). Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness. In 2024, this provider wrote 16 Medicare prescriptions for Neomycin-Polymyxin-Dexameth, about half the volume of the typical Delaware prescriber of this medication (37.7). Medicare paid an average of $15.26 per fill, versus $10.54 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average DE prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 18.7 30-Day Fills standardized to 30-day supplies 433 Days of Medication total across all patients in 2024 | |||
| Travoprost | 15 | $300.11 | ▼ Less than typical |
About Travoprost: Travoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Show more ▾ Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure. A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION. In 2024, this provider wrote 15 Medicare prescriptions for Travoprost, about half the volume of the typical Delaware prescriber of this medication (30.1). Medicare paid an average of $300.11 per fill, versus $190.48 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average DE prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 34.6 30-Day Fills standardized to 30-day supplies 1,017 Days of Medication total across all patients in 2024 | |||
| Minocycline Hcl | 14 | $62.21 | ▼ Less than typical |
About Minocycline Hcl: Minocycline is used to treat a wide variety of infections. Show more ▾ It may also be used along with other medications to treat severe acne. This medication belongs to a class of drugs known as tetracycline antibiotics. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections. A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections. In 2024, this provider wrote 14 Medicare prescriptions for Minocycline Hcl, about half the volume of the typical Delaware prescriber of this medication (31.1). Medicare paid an average of $62.21 per fill, versus $25.96 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average DE prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 32.8 30-Day Fills standardized to 30-day supplies 943 Days of Medication total across all patients in 2024 | |||
About this data. The prescription history for DR. DANIEL JOHN BARUFFI O.D. is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2024, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Optometrist prescribing approach at this Wilmington, DE practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average among DE prescribers of the same medication and form, shown only when at least five prescribers contribute. Always confirm current medications and costs directly with the provider and your plan.
About the medication summaries. Drug use descriptions come from the CMS Medicare Part D Drug Spending Dashboard (2024), and substance definitions from Medical Subject Headings (MeSH) 2026, U.S. National Library of Medicine. They are summaries that do not contain all possible information about a medication and are not individual medical advice. Ask a health care professional about any medication and your specific health needs.
